MedElevator Войти в исследования
← Поиск публикаций

DOI 10.3171/2016.8.jns16626

Медицинская библиотека · Journal of neurosurgery · 2017

Prophylactic nimodipine treatment and improvement in hearing outcome after vestibular schwannoma surgery: a combined analysis of a randomized, multicenter, Phase III trial and its pilot study.

Scheller Christian, Wienke Andreas, Tatagiba Marcos, Gharabaghi Alireza, Ramina Kristofer F, Ganslandt Oliver, Bischoff Barbara, Zenk Johannes, Engelhorn Tobias, Matthies Cordula, Westermaier Thomas, Antoniadis Gregor, Pedro Maria Teresa, Rohde Veit, von Eckardstein Kajetan, Kretschmer Thomas, Kornhuber Malte, Steighardt Jörg, Richter Michael, Barker Fred G, Strauss Christian

Клиническое исследование III фазыСтатьяМногоцентровое исследованиеРандомизированное исследованиеПеревод пока не подготовлен

Аннотация

OBJECTIVE In clinical routines, neuroprotective strategies in neurosurgical interventions are still missing. A pilot study (n = 30) and an analogously performed Phase III trial (n = 112) pointed to a beneficial effect of prophylactic nimodipine and hydroxyethyl starch (HES) in vestibular schwannoma (VS) surgery. Considering the small sample size, the data from both studies were pooled. METHODS The patients in both investigator-initiated studies were assigned to 2 groups. The treatment group (n = 70) received parenteral nimodipine (1-2 mg/hour) and HES (hematocrit 30%-35%) from the day before surgery until the 7th postoperative day. The control group (n = 72) was not treated prophylactically. Facial and cochlear nerve functions were documented preoperatively, during the inpatient care, and 1 year after surgery. RESULTS Pooled raw data were analyzed retrospectively. Intent-to-treat analysis revealed a significantly lower risk for hearing loss (Class D) 12 months after surgery in the treatment group compared with the control group (OR 0.46, 95% CI 0.22-0.97; p = 0.04). After exclusion of patients with preoperative Class D hearing, this effect was more pronounced (OR 0.38, 95% CI 0.17-0.83; p = 0.016). Logistic regression analysis adjusted for tumor size showed a 4 times lower risk for hearing loss in the treatment group compared with the control group (OR 0.25, 95% CI 0.09-0.63; p = 0.003). Facial nerve function was not significantly improved with treatment. Apart from dose-dependent hypotension (p < 0.001), the study medication was well tolerated. CONCLUSIONS Prophylactic nimodipine is safe and may be recommended in VS surgery to preserve hearing. Prophylactic neuroprotective treatment in surgeries in which nerves are at risk seems to be a novel and promising concept. Clinical trial registration no.: DRKS 00000328 ( https://drks-neu.uniklinik-freiburg.de/drks_web/ ).

Для цитирования: Scheller Christian, Wienke Andreas, Tatagiba Marcos, Gharabaghi Alireza, Ramina Kristofer F, Ganslandt Oliver, Bischoff Barbara, Zenk Johannes, Engelhorn Tobias, Matthies Cordula, Westermaier Thomas, Antoniadis Gregor, Pedro Maria Teresa, Rohde Veit, von Eckardstein Kajetan, Kretschmer Thomas, Kornhuber Malte, Steighardt Jörg, Richter Michael, Barker Fred G, Strauss Christian. Prophylactic nimodipine treatment and improvement in hearing outcome after vestibular schwannoma surgery: a combined analysis of a randomized, multicenter, Phase III trial and its pilot study.. Journal of neurosurgery. 2017. DOI: 10.3171/2016.8.jns16626.

Предметные рубрики MeSH

Подготовка и перевод публикации
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…

История · было → стало

Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.

Тип публикации указан по данным источника. Уровень доказательности автоматически не присваивается.